These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33526326)

  • 1. The protective effect of rheumatic disease agents in COVID-19.
    Valenzuela-Almada MO; Putman MS; Duarte-García A
    Best Pract Res Clin Rheumatol; 2021 Mar; 35(1):101659. PubMed ID: 33526326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19.
    Perricone C; Triggianese P; Bartoloni E; Cafaro G; Bonifacio AF; Bursi R; Perricone R; Gerli R
    J Autoimmun; 2020 Jul; 111():102468. PubMed ID: 32317220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
    Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review.
    Atagündüz P; Keser G; Soy M
    Front Immunol; 2021; 12():734279. PubMed ID: 35154066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
    Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
    J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
    Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing rheumatic diseases during COVID-19.
    Ladani AP; Loganathan M; Danve A
    Clin Rheumatol; 2020 Nov; 39(11):3245-3254. PubMed ID: 32895747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 in rheumatic disease patients on immunosuppressive agents.
    Sharmeen S; Elghawy A; Zarlasht F; Yao Q
    Semin Arthritis Rheum; 2020 Aug; 50(4):680-686. PubMed ID: 32512263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
    Park JK; Lee EB; Shin K; Sung YK; Kim TH; Kwon SR; Lee MS; Hong SJ; Choi BY; Lee SS; Back HJ;
    J Korean Med Sci; 2021 Mar; 36(12):e95. PubMed ID: 33783147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study.
    Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
    Atzeni F; Gerratana E; Giallanza M; La Corte L; Nucera V; Miceli G; Sangari D; Masala IF
    Expert Opin Biol Ther; 2021 Feb; 21(2):219-228. PubMed ID: 32866053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
    Sarzi-Puttini P; Marotto D; Antivalle M; Salaffi F; Atzeni F; Maconi G; Monteleone G; Rizzardini G; Antinori S; Galli M; Ardizzone S
    Autoimmun Rev; 2020 Jul; 19(7):102574. PubMed ID: 32376399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
    Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH
    Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).
    Frodlund M; Nived P; Chatzidionysiou K; Södergren A; Klingberg E; Hansson M; Ohlsson S; Pin E; Bengtsson A; Klareskog L; Kapetanovic M
    Microbiol Spectr; 2024 Apr; 12(4):e0298123. PubMed ID: 38441463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak.
    Sonaglia A; Comoretto R; Pasut E; Treppo E; Del Frate G; Colatutto D; Zabotti A; De Vita S; Quartuccio L
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
    Mikuls TR; Johnson SR; Fraenkel L; Arasaratnam RJ; Baden LR; Bermas BL; Chatham W; Cohen S; Costenbader K; Gravallese EM; Kalil AC; Weinblatt ME; Winthrop K; Mudano AS; Turner A; Saag KG
    Arthritis Rheumatol; 2020 Aug; 72(8):1241-1251. PubMed ID: 32349183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
    Favalli A; Favalli EG; Gobbini A; Zagato E; Bombaci M; Maioli G; Pesce E; Donnici L; Gruarin P; Biggioggero M; Curti S; Manganaro L; Marchisio E; Bevilacqua V; Martinovic M; Fabbris T; Sarnicola ML; Crosti M; Marongiu L; Granucci F; Notarbartolo S; Bandera A; Gori A; De Francesco R; Abrignani S; Caporali R; Grifantini R
    Front Immunol; 2022; 13():873195. PubMed ID: 35757699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2-specific T-cell responses after COVID-19 recovery in patients with rheumatic diseases on immunosuppressive therapy.
    Lledó A; Retuerto M; Almendro-Vázquez P; Fernández-Ruiz M; Galindo M; Laguna-Goya R; Paz-Artal E; Lalueza A; Aguado JM; Pablos JL
    Semin Arthritis Rheum; 2021 Dec; 51(6):1258-1262. PubMed ID: 34775160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.